Cargando…

Treatment of HCV NS3/4a Protease Inhibitor Experienced Patients with Sofosbuvir Containing Regimens in an Outpatient Clinic

BACKGROUND: We assessed the success rate of retreatment with a sofosbuvir containing regimen in HIV/ HCV genotype 1 coinfected patients who failed a regimen containing a HCV protease inhibitor in a HIV Primary care clinic. METHODS: A retrospective review of outpatient medical records was conducted t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilroy, Shelley, Choudhary, Madhuchanda, Faragon, John, Ells, Peter, Kingsley, Zoe, Cirabisi, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631297/ http://dx.doi.org/10.1093/ofid/ofx163.1755

Ejemplares similares

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients
por: Ajlan, A., et al.
Publicado: (2016)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
por: Soumana, Djadé I., et al.
Publicado: (2014)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
por: McQuaid, Thomas, et al.
Publicado: (2015)

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships
por: Hu, Katherine, et al.
Publicado: (2020)

Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener
por: B, Uma Reddy, et al.
Publicado: (2020)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
por: Mazzitelli, Maria, et al.
Publicado: (2018)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
por: Huhn, Gregory D., et al.
Publicado: (2020)

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
por: Wei, Lai, et al.
Publicado: (2018)

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis
por: Mariantonietta, Pisaturo, et al.
Publicado: (2019)

Engineered Toxins “Zymoxins” Are Activated by the HCV NS3 Protease by Removal of an Inhibitory Protein Domain
por: Shapira, Assaf, et al.
Publicado: (2011)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation
por: Cenderello, Giovanni, et al.
Publicado: (2015)

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
por: Luetkemeyer, Anne F., et al.
Publicado: (2016)

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
por: Kayali, Zeid, et al.
Publicado: (2014)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease
por: Omar, Abdelsattar M., et al.
Publicado: (2020)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease
por: Wadood, Abdul, et al.
Publicado: (2013)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy
por: Dietz, Julia, et al.
Publicado: (2016)

The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease
por: Khan, Mahim, et al.
Publicado: (2022)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region
por: Hamad, Hamzah A., et al.
Publicado: (2016)

Sofosbuvir improves HCV‐induced insulin resistance by blocking IRS1 degradation
por: Rey, Esther, et al.
Publicado: (2021)

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
por: Han, Qunying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6ecpgqsusc2ekgpa2q8ulrsck4